Men Older Than 70 Years Have Higher Risk Prostate Cancer and Poorer Survival in the Early and Late Prostate Specific Antigen Eras

Department of Surgery, Duke University, Durham, North Carolina, United States
The Journal of urology (Impact Factor: 4.47). 09/2009; 182(5):2242-8. DOI: 10.1016/j.juro.2009.07.034
Source: PubMed


We clarified whether men older than 70 years have a higher risk of prostate cancer and poorer survival in the early and late prostate specific antigen eras.
A cohort of 4,561 men who underwent radical prostatectomy were stratified into 3 age groups (younger than 60, 60 to 70 and older than 70 years), and early and late prostate specific antigen eras based on the year of surgery (before 2000 and 2000 or later). Race, body mass index, prostate specific antigen, prostate weight, tumor volume, pathological Gleason sum, pathological tumor stage, extracapsular extension, seminal vesicle invasion and surgical margin status were submitted for univariate and multivariable analyses against the previously mentioned groups. Survivals (prostate specific antigen recurrence, distant metastasis and disease specific death) were compared among the 3 age groups using univariate and multivariable methods.
Compared with younger age groups (younger than 60, 60 to 70 years) men older than 70 years had a higher proportion of pathological tumor stage 3/4 (33.0 vs 44.3 vs 52.1%, p <0.001), pathological Gleason sum greater than 7 (9.5% vs 13.4% vs 17.2%, p <0.001) and larger tumor volume (3.7 vs 4.7 vs 5.2 cc, p <0.001). Pathological Gleason sum in men older than 70 years did not differ between the early and late prostate specific antigen eras (p = 0.071). Men older than 70 years had a higher risk of prostate specific antigen recurrence, distant metastasis and disease specific death on univariate (p <0.05) but not multivariable analysis.
Men older than 70 years had higher risk disease and poorer survival in the early and late prostate specific antigen eras. Pathological Gleason sums did not change between the 2 eras. Patient age was an important variable in prostate specific antigen screening, biopsy, treatment and prognosis.

1 Follower
13 Reads
  • Source
    • "Since, the thymus is the principal organ responsible for T cell maturation [20], which continues to grow between birth and puberty, and that thymic activity (T-cell output) is the most active before puberty and undergoes atrophy in aging, inevitably weakening the immune response [21]; it can thus be inferred that there is a positive correlation between cancer and age [22]. Therefore, it would not be very surprising to think of the immune system as key to cancer therapy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: T-cells play an important role in the immune response and are activated in response to the presentation of antigens bound to major histocompatibility complex (MHC) molecules participating with the T-cell receptor (TCR). T-cell receptor complexes also contain four CD3 (cluster of differentiation 3) subunits. The TCR-CD3 complex is vital for T-cell development and plays an important role in intervening cell recognition events. Since microRNAs (miRNAs) are highly stable in blood serum, some of which may target CD3 molecules, they could serve as good biomarkers for early cancer detection. The aim of this study was to see whether there is a relationship between cancers and the amount of miRNAs -targeted CD3 molecules. Bioinformatics tools were used in order to predict the miRNA targets for these genes. Subsequently, these highly conserved miRNAs were evaluated to see if they are implicated in various kinds of cancers. Consequently, human disease databases were used. According to the latest research, this study attempted to investigate the possible down- or upregulation of miRNAs cancer patients. We identified miRNAs which target genes producing CD3 subunit molecules. The most conserved miRNAs were identified for the CD3G gene, while CD247 and CD3EAP genes had the least number and there were no conserved miRNA associated with the CD3D gene. Some of these miRNAs were found to be responsible for different cancers, following a certain pattern. It is highly likely that miRNAs affect the CD3 molecules, impairing the immune system, recognizing and destroying cancer tumor; hence, they can be used as suitable biomarkers in distinguishing cancer in the very early stages of its development.
    PLoS ONE 11/2013; 8(11):e78790. DOI:10.1371/journal.pone.0078790 · 3.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hintergrund Das Ziel dieser Studie ist die Evaluierung der perioperativen, onkologischen und funktionellen Ergebnisse nach roboterassistierter laparoskopisch radikaler Prostatektomie (RALP) bei älteren Männern. Patienten und Methoden Die Datensätze von 2000 Männern, die sich im Zeitraum von Februar 2006 bis April 2010 einer RALP unterzogen, wurden retrospektiv analysiert. Insgesamt wurden 45 Patienten ≥ 75 Jahre identifiziert. Anschließend wurde diese Subgruppe mit dem übrigen gesamten Patientenkollektiv hinsichtlich der perioperativen Resultate, des pathologischen Tumorstadiums, der funktionellen Ergebnisse nach 12 Monaten, sowie der prostatakarzinomspezifischen Mortalität und des biochemischen rezidivfreien Überlebens verglichen. Ergebnisse Die folgenden Ergebnisse spiegeln den Vergleich der Patientensubgruppe mit einem Alter ≥ 75 Jahren und dem Gesamtkollektiv wieder. Ein statistisch signifikanter Unterschied konnte nur bei der Rate an leichtgradigen Komplikationen mit 15,5% vs. 11,4% (p < 0,05), beim durchgeführten Nerverhalt mit 51,1% vs. 65,7% (p < 0,05) und der postoperativen Potenz nach 12 Monaten mit 39,6% vs. 66,2% (p < 0,001) beobachtet werden. Schwerwiegende Komplikationen wurden in 2,2% gegenüber 1,3% der Fälle festgestellt. Ein Gleason-Score < 7 lag in 37,3% vs. 42,8%, ein Gleason-Score von 7 in 51,1% vs. 47,7% und ein Gleason-Score > 7 in 11,6% vs. 9,5% vor. Ein pT2-Stadium wurde in 68,8% vs. 73,5% und ein pT3-Stadium in 31,2% vs. 25,2% festgestellt. Die Rate an positiven Resektionsrändern lag bei 11,1% vs. 8,9%. Nach 12 Monaten waren 86,9% vs. 92,8% der Patienten kontinent und 39,6% vs. 66,2% potent. Nach einem medianen Follow-up von 17,2 Monaten lag die prostatakarzinomspezifische Mortalität in der Subgruppe der älteren Patienten bei 0% und das biochemische rezidivfreie Überleben bei 95,5%. Schlussfolgerung Die RALP stellt auch bei Patienten ≥ 75 Jahre ein sicheres Operationsverfahren mit akzeptabler Komplikationsrate, sehr guten onkologische Ergebnissen und postoperativer Kontinenz, sowie akzeptabler erektiler Funktion dar. Dennoch sollte die Indikation zur RALP in fortgeschrittenem Alter auf selektionierte Patienten mit einem guten allgemeinen Gesundheitszustand und einer individuellen Lebenserwartung ≥ 10 Jahren begrenzt werden. Zur Beurteilung des endgültigen onkologischen Benefits der RALP in diesem Patientengut ist jedoch ein längeres Follow-up notwendig.
    Der Urologe 10/2012; 51(10). DOI:10.1007/s00120-012-2925-3 · 0.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We discuss adaptive behavior acquisition for collision avoidance among multiple autonomous mobile robots which are equipped with the locally communicable infrared sensory system (LOCISS). The LOCISS is a local sensing device for collision avoidance by which robots can detect other robots and obstacles and discriminate them by exchanging relevant information. We (1996) reported previously a collision avoidance method between two robots based on the predetermined rules using LOCISS. It is, however, difficult to realize collision avoidance among three or more robots by the predetermined rules only because situations around the robots become more complicated as the number of robots increases. Thus, it is desirable for the robots to have an adaptive capability for acquisition of the behaviors to avoid collision with other robots and obstacles. To acquire the adaptive behavior, the reinforcement learning is introduced in this paper. It is shown that appropriate behaviors for collision avoidance can be successfully acquired through the proposed learning process
    Intelligent Robots and Systems, 1997. IROS '97., Proceedings of the 1997 IEEE/RSJ International Conference on; 10/1997
Show more